{
  "id": 16641286,
  "title": "Overcoming Bottlenecks: Biopharma’s Big Challenge Is Execution",
  "url": "https://urgent.news/2026/10/26/overcoming-bottlenecks-biopharmas-big-challenge-is-execution",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-26T18:22:52.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/bioprocessing/overcoming-bottlenecks-biopharmas-big-challenge-is-execution/"
  },
  "original_language": "en",
  "account": "The most significant challenge for the biopharma sector is not scientific innovation, but rather the execution of manufacturing processes. Nicolas Pivet, vice president and general manager of manufacturing and digital solutions at Cytiva, noted that despite major scientific breakthroughs such as RNA technologies and cell and gene interventions, the industry's manufacturing capabilities have not kept pace. Pivet emphasized that the industry often focuses on surface-level issues, such as paper batch records and disconnected systems, rather than addressing the root cause: manufacturing environments that have evolved over decades without being designed as connected systems. These older systems lack integration and data-rich insights, leading to a visibility problem and poor decision-making.\n\nTo overcome these bottlenecks, Pivet advises prioritizing observability to gain early insights into process deviations, which enables better decision-making and confidence in outcomes. This observability forms the foundation for advanced manufacturing, data integration, and predictive analytics. Only after establishing a reliable data foundation should organizations consider advanced control and AI-enabled decision-making. The barriers to digital transformation are primarily organizational rather than technical, as biopharma companies often view change as riskier than maintaining status quo. Trust is built through consistent performance, so successful organizations demonstrate value through real-world manufacturing improvements before scaling initiatives.\n\nMoreover, preparing the workforce is crucial for successful digital transformation. Traditional skillsets are evolving, with emerging roles requiring data literacy, systems thinking, automation fluency, and cross-functional collaboration. Biopharma companies must upskill their employees and foster immersive learning experiences to bridge the skills gap. In the coming years, hybrid roles combining process and digital expertise will become increasingly common, and organizations that invest in workforce readiness will be better positioned to thrive in the digital manufacturing landscape.",
  "summary": "The biggest challenge facing the biopharma industry isn’t scientific innovation. It’s manufacturing execution. Closing this gap is one of the greatest opportunities biopharma has today to enhance resilience and unlock the full value of its science. The post Overcoming Bottlenecks: Biopharma’s Big Challenge Is Execution appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}